ProMIS Neurosciences (TSE:PMN), a biopharma penny stock, advanced after announcing that it has identified a fifth novel therapeutic target
Sean Mason | June 21, 2016 | SmallCapPower
A therapeutic target for the treatment of Alzheimer’s disease boosted a biopharma penny stock Tuesday. Here’s some small stocks making big moves on Tuesday, June 21, 2016 (as of 4 pm EST):
Biopharma penny stock ProMIS Neurosciences (TSE:PMN) shares shot up 77% to $0.195 on Tuesday after the drug development company announced that it has identified and submitted a provisional patent application for a fifth novel therapeutic target on prion-like strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer’s disease.
As well, shares of Dundee Precious Metals Inc. (TSX:DPM) slipped 9% to $2.97 as the international gold mining company said it has entered into a $50 million bought deal financing agreement at a price of $3 per share.
Helius Medical Technologies, Inc. (TSE:HSM), meanwhile, reported positive results of a case series of individuals with advanced symptoms of Multiple Sclerosis treated with PoNS Therapy. Helius Medical Technologies stock moved up 7% to $1.30 following the announcement.
Finally, Noram Ventures Inc. (CVE:NRM) shares gained 25% to $0.075 after the junior explorer announced that it is expanding the surface and sub-surface sampling being conducted on its South Block Extension to include its Zeus and Spartan lithium brine/clay claim groups.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source.
